Current Treatmentsof Deep Venous Thrombosis
Abstract
Venous thromboembolism is a disease spectrum that encompasses all pathologic thrombotic conditions observed in human venous system. It is most frequently seen in lower extremity deep veins where it is named as deep vein thrombosis. However, it might also be detected in upper extremity, pelvic and other venous systems of the body. Pulmonary embolism is the life-threatening component of venous thromboembolism. Rapid diagnosis and optimal treatment of are vital for decreasing patient mortality, morbidity, and the incidence of recurrent events. Initial treatment with unfractionated heparin, low-molecular weight heparin, or fondaparinux overlapped with warfarin is the currently approved treatment in most cases. Warfarin monotherapy is then continued for a time period which depends on the specific conditon of patients. These current treatment guidelines were published before the approval of new oral anticoagulants. The advantages of new oral anticoagulants are the ease of use, reduced monitoring requirements, and probably lower bleeding risk than warfarin therapy. This review addresses the current treatment of venous thromboembolism, with a particular emphasis on new oral anticoagulants.
Keywords
Deep vein thrombosis, Dabigatran, Apixaban, Rivoraxaban, Warfarin
Kaynakça
- Güven Platformu. Ulusal Venöz Tromboembolizm Profilaksi ve Tedavi Kılavuzu. 2010
- Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physician Evidence-based Clinical Practical Guidelines. Chest. 2012; 41:7-47.
- Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N et al. ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society. Eur Heart J. 2014;35:3033-69.
- Lee CH, Hankey GJ, Ho WK, Eikelboom JW. Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust. 2005;182:569-74.
- Rosendal FR. Risk factors for venous thrombosis: prevelance, risk, and interaction. Semin Hematol. 1997;34:171-87.
- Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107: 9-16.
- Wells P, Forgie MA, Rodger MA. Treatment of venous thromboembolism JAMA. 2014;311:717-28.
- Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: clinical review. Journal of Blood Medicine. 2011;2:59-69.
- Kurtoglu MH, Sivrikoz E. Derin ven trombozu: tanı, tedavi, proflaksi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2008;5:34-42.
- Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep venous thrombosis. Arch Intern Med. 1997;157:2562-8.
